World Hemophilia Day: Sanofi Genzyme donation impacts patients across the globe
- Details
- Category: Sanofi
On World Hemophilia Day April 17th, the global bleeding disorders community unites to raise awareness and understanding of hemophilia and areas of unmet needs for patients. Hemophilia is a rare, genetic bleeding disorder in which the ability of a person's blood to clot is impaired, which can lead to bleeding episodes that can cause pain, irreversible joint damage, and life-threatening hemorrhages.
Independent large real-world study comparing NOACs in AF-patients
- Details
- Category: Boehringer Ingelheim
The results from an independent retrospective comparative study, published in January 2019 in the American Journal of Medicine, showed that dabigatran was associated with a more favourable benefit-harm profile than both warfarin and rivaroxaban.
EVENITY™ (romosozumab-aqqg) now available in the United States for the treatment of osteoporosis in postmenopausal women at high risk for fracture
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
Bristol-Myers Squibb shareholders approve Celgene acquisition
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company's pending merger with Celgene Corporation (NASDAQ:CELG) at the Special Meeting of Stockholders.
FDA approves EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture.
Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off
- Details
- Category: Novartis
Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depositary Receipts), with each holder receiving 1 Alcon share for every 5 Novartis shares or ADRs held on April 8, 2019, at the close of business.
Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
- Details
- Category: Sanofi
Sanofi and Alnylam have agreed to conclude the research and option phase of the companies' 2014 RNAi therapeutics alliance in rare genetic diseases. The material collaboration terms for patisiran, vutrisiran (ALN-TTRsc02) and fitusiran, as previously announced, will continue unchanged.
More Pharma News ...
- Boehringer Ingelheim enhances oncology R&D with novel MacroDel delivery technology via acquisition of ICD Therapeutics
- Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre
- Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1
- AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
- Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
- Forxiga approved in Japan for type-1 diabetes
- Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD